Request Discount

Anticoagulant Reversal Drugs Market (Product Type - Prothrombin Complex Concentrates, Vitamin K, Protamine, Tranexamic Acid, Idarucizumab, Andexxa, and Other Product Types; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, and Others Distribution Channels): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025

  • Published : January, 2020

  • Rep Id : HC0779

  • Category : Healthcare & Medical Devices

  • Status : Published

This report provides exclusive insights into the COVID-19 impact on the Anticoagulant Reversal Drugs Market. The detailed analysis provides information about the impact of the outbreak on the demand and supply conditions, trends and forecasts of the Anticoagulant Reversal Drugs Market. Moreover, the impact analysis covers the study of the COVID-19 on the supply chain of Anticoagulant Reversal Drugs Market. The sectoral impact shall provide insights into both short term and long term effects of the pandemic on the related and support industries.

A recent report published by Infinium Global Research on the anticoagulant reversal drugs market provides an in-depth analysis of segments and sub-segments in the global as well as regional anticoagulant reversal drugs market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional anticoagulant reversal drugs market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of the global anticoagulant reversal drugs market. According to the report, the global anticoagulant reversal drugs market is projected to grow at a CAGR of 11.5 % over the forecast period of 2019-2025.

 

Market Insight

Anticoagulant reversal drugs are required when there is a need to neutralize anticoagulant therapy in a situation, where there is a complication of bleeding such as in heart attack or stroke. Andexxa is the only drug launched by the Portola Pharmaceuticals Inc. that is used for reversing the effect of factor Xa inhibitors. It is used, when people are suffering from severe complications from blood clots. Additionally, in 2019, Portola Pharmaceuticals Inc. has launched Andexxa with the name Ondexxya in Europe and there are fewer side effects of it. The objective of this launch is to manage the availability of Andexxa to as many hospitals and patients as possible to meet their higher requirements. This will help to increase the sale of the Andexxa in the hospital, which in turn boosts the anticoagulant reversal drugs.

 

The rise in the prevalence of atrial fibrillation and cardiovascular disease is the factor, which is likely to boost this market. As it is found that cardiovascular disease mainly found in the adult. For instance, about 40 % of the adult population in the United States were diagnosed with a cardiovascular condition in 2018. Therefore, the growing aging population is anticipated to experience the rapid growth of the market. On the other hand, the approval of blockbuster drugs in recent years such as Andexxa and a strong pipeline are contributing to the growth of the market. The increasing focus of the company in the R&D activities which, in turn, propels the market. The government is taking initiatives towards the healthcare expenditure, which helps to drive for the market. However, the availability of the high cost of the patent drugs yet remains one of the major restraints to this market. Moreover, many companies are taking initiative to launch the drug, which is used for reversing the effect of factor Xa inhibitors offer favorable opportunities in this market.

 

Geographically, North America is the dominant region in this market and is expected to hold the maximum market share in the forecast period owing to increasing drug approval by the USFDA as well as involving in the prevention program of the blood disorder such as by Centers for Disease Control and Prevention. On another hand, Europe holds the second-largest market share in this market due to the recent launch of the Ondexxya and the continuous growth of the R&D activities by the companies.

 

Segment Covered

The report on global anticoagulant reversal drugs market covers segments such as product type, and distribution channel. On the basis of product type, the sub-markets include prothrombin complex concentrates, vitamin k, protamine, tranexamic acid, idarucizumab, andexxa, and other product types. On the basis of distribution channel, the sub-markets include hospital pharmacies, retail pharmacies, and others distribution channels.

 

Companies Profiled:

The report provides profiles of the companies in the market such as Bausch Health Companies, Inc., Pfizer, Inc., Fresenius Kabi AG, Amneal Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, CSL Limited, Octapharma AG, Portola Pharmaceuticals, Inc., and Perosphere Pharmaceuticals, Inc.

 

Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the anticoagulant reversal drugs market. Moreover, the study highlights current market trends and provides forecast from 2019-2025. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.


Other Reports in This Category
24 hour delivery through email
9923950043 Monday to Frieday 9am-7pm
looking for discount